Abstract
IntroductionNatalizumab, approved for 300 mg intravenous every-4-weeks dosing, is associated with PML risk. Prior studies have been inconclusive regarding EID’s impact on PML risk. The US REMS program (TOUCH) offers...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have